Resource Summary Report

Generated by nidm-terms on Aug 11, 2026

CD8 Monoclonal Antibody (SP16)

RRID:AB_10984334
Type: Antibody

Proper Citation

(Thermo Fisher Scientific Cat# MA5-14548, RRID:AB_10984334)

Antibody Information

URL: http://antibodyregistry.org/AB_10984334

Proper Citation: (Thermo Fisher Scientific Cat# MA5-14548, RRID:AB_10984334)

Target Antigen: CD8

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: Flow, IHC-P

Antibody Name: CD8 Monoclonal Antibody (SP16)

Description: This monoclonal targets CD8

Target Organism: human

Clone ID: Clone SP16

Defining Citation: PMID:23716548, PMID:21494640, PMID:20579277, PMID:21129807, PMID:26660641, PMID:22495453, PMID:18354379, PMID:17947831, PMID:19168793, PMID:21995633, PMID:24331841, PMID:20628202, PMID:24336331, PMID:26714314, PMID:24808637, PMID:27213174, PMID:22241988, PMID:20594146, PMID:21537083, PMID:17133491, PMID:24367907, PMID:18048854, PMID:26426650

Antibody ID: AB_10984334

Vendor: Thermo Fisher Scientific

Catalog Number: MA5-14548

Record Creation Time: 20251213T073826+0000

Record Last Update: 20260225T231013+0000

Ratings and Alerts

No rating or validation information has been found for CD8 Monoclonal Antibody (SP16).

No alerts have been found for CD8 Monoclonal Antibody (SP16).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at nidm-terms .

Zhou L, et al. (2026) p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy. Cancer discovery, 16(3), 571.

Chen C, et al. (2026) B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity. Cancer cell.

Wei S, et al. (2026) A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma. Cell reports. Medicine, 7(4), 102716.

Yu H, et al. (2025) UDP-GlcUA triggers PKR kinase activity to promote liquid-liquid phase separation of TOP2A and enhances radioimmunotherapy resistance. Molecular cell, 85(21), 3913.

Srinivasan S, et al. (2025) Development of a First-in-Class Click Chemistry-Based Cancer Therapeutic, from Preclinical Evaluation to a First-in-Human Dose Escalation Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(17), 3662.

Weeden CE, et al. (2023) Early immune pressure initiated by tissue-resident memory T??cells sculpts tumor evolution in non-small cell lung cancer. Cancer cell, 41(5), 837.

Liu X, et al. (2023) Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity. Cancer cell, 41(6), 1073.

Eyraud E, et al. (2023) Short-range interactions between fibrocytes and CD8+ T cells in COPD bronchial inflammatory response. eLife, 12.

Ouyang Y, et al. (2023) FGFR3 Alterations in Bladder Cancer Stimulate Serine Synthesis to Induce Immune-Inert Macrophages That Suppress T-cell Recruitment and Activation. Cancer research, 83(24), 4030.

Bruand M, et al. (2021) Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell reports, 36(3), 109412.

Dangaj D, et al. (2019) Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Cancer cell, 35(6), 885.

Lee JJ, et al. (2019) Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma. Cell, 177(7), 1842.

Su S, et al. (2018) Immune Checkpoint Inhibition Overcomes ADCP-Induced Immunosuppression by Macrophages. Cell, 175(2), 442.